{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T03:11:14Z","timestamp":1726024274992},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,2,6]],"date-time":"2007-02-06T00:00:00Z","timestamp":1170720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Obesity Reviews"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This paper aims to assess the cost\u2010effectiveness of sibutramine in treating obese patients in the Western countries. The model estimates the costs and quality of life benefits directly associated with weight losses combined with the costs and benefits associated with the reduced incidence of coronary heart disease (CHD) and diabetes. The pivotal effectiveness evidence is derived from a German multicentre, double\u2010blind, randomized clinical trial on obese (body mass index\u2003\u2265\u2003\u20ac30\u2003kg\u2003m<jats:sup>\u22122<\/jats:sup>) patients. The incremental cost per quality\u2010adjusted life year ranges from \u20ac10\u2003734 in Switzerland to \u20ac13\u2003707 in Germany. The total number of CHD events avoided ranges from 1.96 for the UK to 4.49 for Switzerland. The number of diabetes cases avoided is in the region of 3.0 (ranges from 2.58 for Germany to 3.28 for Switzerland). The majority of costs and benefits are accrued through sibutramine treatment and monitoring. Univariate sensitivity analyses show that results are sensitive to changes in the utility directly attributable to weight losses. The results demonstrate that the benefits associated with sibutramine\u2010induced weight losses are obtained at a reasonable cost in each of the settings explored and suggest that sibutramine treatment could be considered as a viable option for pharmacotherapy treatment alongside diet and exercise.<\/jats:p>","DOI":"10.1111\/j.1467-789x.2007.00352.x","type":"journal-article","created":{"date-parts":[[2007,2,6]],"date-time":"2007-02-06T11:51:47Z","timestamp":1170762707000},"page":"363-371","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The cost\u2010effectiveness of sibutramine in non\u2010diabetic obese patients: evidence from four Western countries"],"prefix":"10.1111","volume":"8","author":[{"given":"R.","family":"Ara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,2,6]]},"reference":[{"key":"e_1_2_8_2_2","unstructured":"Obesity in Europe: the International Obesity Task Force and European Association for the Study of Obesity.Case for Action. [WWW document]. URLhttp:\/\/www.iotf.org\/media\/euobesity.pdf(accessed 23 May 2006)."},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.10.1188"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000107400.72456.19"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802714"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802870"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000145546.97738.1E"},{"key":"e_1_2_8_8_2","unstructured":"Association for the Study of Obesity.The Composition of the Human Body. [WWW document]. URLhttp:\/\/www.aso.org.uk\/portal.asp?oricmid=156&orictype=header&targetcell=3 0&targetwidth=4&functionname=aso_oric#oricarticle(accessed 23 May 2006)."},{"key":"e_1_2_8_9_2","unstructured":"National Institute of Clinical Excellence.Final Scope: Obesity. [WWW document]. URLhttp:\/\/www.nice.org.uk\/page.aspx?o=211305(accessed 23 May 2006)."},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X03261565"},{"key":"e_1_2_8_11_2","doi-asserted-by":"crossref","unstructured":"BrennanA AraR StertzR. MatibaB BergmannR.Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany.Eur J Health Econ2006(in press).","DOI":"10.1007\/s10198-006-0374-x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-817934"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.83.1.356"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.67.5.968"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-7-199504010-00001"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1999.tb00436.x"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801035"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03491-7"},{"key":"e_1_2_8_19_2","first-page":"505","article-title":"Randomized placebo\u2010controlled trial of long\u2010term treatment with sibutramine in mild to moderate obesity","volume":"50","author":"Smith IG","year":"2001","journal-title":"J Fam Pract"},{"key":"e_1_2_8_20_2","unstructured":"Reductil Summary of Product Characteristics. [WWW document]. URLhttp:\/\/emc.medicines.org.uk(accessed January 2005)."},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00103-6"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7133.736"},{"key":"e_1_2_8_23_2","volume-title":"Health and Functional Capacity in Finland. Baseline Results of the Health 2000 Health Examination Survey.","author":"Aromaa A","year":"2004"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.80.1.40"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00361-4"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/027298902400448902"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-22671"},{"key":"e_1_2_8_28_2","volume-title":"Syd\u00e4ninfarktipotilaan hoitoketjun toimivuus ja hoitokustannusten potilaskohtainen jakautuminen Etel\u00e4\u2010Pohjanmaalla","author":"Kettula M.","year":"2001"},{"key":"e_1_2_8_29_2","unstructured":"HujanenT.Terveydenhuollon yksikk\u00f6kustannukset Suomessa vuonna 2001.Stakes Aiheita 1\/2003. National Public Health Institute. The Health 2000 data on filehttp:\/\/www.ktl.fi\/health2000\/(accessed March 2004)."},{"key":"e_1_2_8_30_2","volume-title":"Diabeetikkojen terveyspalvelut ja niiden kustannukset.","author":"Kangas T.","year":"2002"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s003920050381"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-002-0858-x"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2003.00972.x"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7160.720"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7246.1373"},{"key":"e_1_2_8_36_2","first-page":"1410","article-title":"Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?","volume":"25","author":"Colagiuri S","year":"2002","journal-title":"UKPDS Study 61"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7250.1627"}],"container-title":["Obesity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1467-789X.2007.00352.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1467-789X.2007.00352.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T02:59:40Z","timestamp":1697252380000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1467-789X.2007.00352.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,6]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1111\/j.1467-789X.2007.00352.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1467-789x.2007.00352.x","archive":["Portico"],"relation":{},"ISSN":["1467-7881","1467-789X"],"issn-type":[{"value":"1467-7881","type":"print"},{"value":"1467-789X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,6]]},"assertion":[{"value":"2007-02-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}